Investors Asset Management of Georgia Inc. GA ADV Makes New $202,000 Investment in Becton, Dickinson and Company $BDX

Investors Asset Management of Georgia Inc. GA ADV acquired a new stake in shares of Becton, Dickinson and Company (NYSE:BDX) in the second quarter, HoldingsChannel reports. The firm acquired 1,175 shares of the medical instruments supplier’s stock, valued at approximately $202,000.

A number of other hedge funds and other institutional investors also recently added to or reduced their stakes in BDX. Saudi Central Bank bought a new position in shares of Becton, Dickinson and Company during the 1st quarter valued at approximately $26,000. Smallwood Wealth Investment Management LLC purchased a new stake in Becton, Dickinson and Company during the first quarter valued at $27,000. Alpine Bank Wealth Management bought a new position in Becton, Dickinson and Company during the first quarter valued at $29,000. Cornerstone Planning Group LLC grew its stake in shares of Becton, Dickinson and Company by 341.4% in the 1st quarter. Cornerstone Planning Group LLC now owns 128 shares of the medical instruments supplier’s stock worth $29,000 after buying an additional 99 shares in the last quarter. Finally, Kelly Lawrence W & Associates Inc. CA bought a new stake in shares of Becton, Dickinson and Company in the 1st quarter worth about $31,000. 86.97% of the stock is owned by institutional investors.

Analyst Ratings Changes

A number of research analysts recently commented on the stock. Wall Street Zen raised shares of Becton, Dickinson and Company from a “hold” rating to a “buy” rating in a report on Saturday, August 9th. Morgan Stanley raised their price objective on Becton, Dickinson and Company from $196.00 to $197.00 and gave the company an “overweight” rating in a research note on Monday, August 11th. Wells Fargo & Company boosted their target price on Becton, Dickinson and Company from $172.00 to $184.00 and gave the company an “equal weight” rating in a research report on Friday, August 8th. Weiss Ratings restated a “hold (c-)” rating on shares of Becton, Dickinson and Company in a research report on Saturday, September 27th. Finally, Argus lifted their price objective on shares of Becton, Dickinson and Company from $220.00 to $230.00 in a research note on Monday, September 15th. Three investment analysts have rated the stock with a Buy rating and nine have issued a Hold rating to the stock. According to MarketBeat, the company currently has a consensus rating of “Hold” and a consensus price target of $205.40.

Becton, Dickinson and Company Price Performance

BDX opened at $193.67 on Monday. The business has a fifty day moving average of $189.03 and a 200 day moving average of $187.06. The stock has a market cap of $55.51 billion, a P/E ratio of 34.83, a PEG ratio of 1.51 and a beta of 0.25. The company has a quick ratio of 0.62, a current ratio of 1.10 and a debt-to-equity ratio of 0.69. Becton, Dickinson and Company has a 52-week low of $163.33 and a 52-week high of $251.99.

Becton, Dickinson and Company (NYSE:BDX) last released its earnings results on Thursday, August 7th. The medical instruments supplier reported $3.68 earnings per share for the quarter, topping analysts’ consensus estimates of $3.40 by $0.28. The business had revenue of $5.51 billion for the quarter, compared to analyst estimates of $5.50 billion. Becton, Dickinson and Company had a return on equity of 16.23% and a net margin of 7.51%.The business’s revenue was up 10.4% compared to the same quarter last year. During the same quarter last year, the firm posted $3.50 earnings per share. Becton, Dickinson and Company has set its FY 2025 guidance at 14.300-14.450 EPS. As a group, sell-side analysts anticipate that Becton, Dickinson and Company will post 14.43 EPS for the current year.

Becton, Dickinson and Company Dividend Announcement

The business also recently disclosed a quarterly dividend, which was paid on Tuesday, September 30th. Shareholders of record on Monday, September 8th were given a $1.04 dividend. This represents a $4.16 annualized dividend and a yield of 2.1%. The ex-dividend date of this dividend was Monday, September 8th. Becton, Dickinson and Company’s payout ratio is 74.82%.

Insider Transactions at Becton, Dickinson and Company

In related news, EVP Michael David Garrison sold 1,185 shares of the stock in a transaction that occurred on Friday, July 18th. The stock was sold at an average price of $180.29, for a total value of $213,643.65. Following the transaction, the executive vice president owned 4,887 shares of the company’s stock, valued at $881,077.23. This represents a 19.52% decrease in their ownership of the stock. The sale was disclosed in a document filed with the Securities & Exchange Commission, which is available through the SEC website. Also, Director Claire Fraser sold 917 shares of the firm’s stock in a transaction on Wednesday, September 10th. The stock was sold at an average price of $187.50, for a total value of $171,937.50. Following the transaction, the director owned 22,226 shares in the company, valued at $4,167,375. The trade was a 3.96% decrease in their ownership of the stock. The disclosure for this sale can be found here. Insiders sold a total of 3,023 shares of company stock worth $562,036 over the last 90 days. Insiders own 0.36% of the company’s stock.

Becton, Dickinson and Company Profile

Becton, Dickinson and Company develops, manufactures, and sells medical supplies, devices, laboratory equipment, and diagnostic products for healthcare institutions, physicians, life science researchers, clinical laboratories, pharmaceutical industry, and the general public worldwide. The company operates in three segments: BD Medical, BD Life Sciences, and BD Interventional.